Literature DB >> 26289945

The effects of single nucleotide polymorphisms in glutamatergic neurotransmission genes on neural response to alcohol cues and craving.

Patrick Bach1, Martina Kirsch1, Sabine Hoffmann1, Anne Jorde1, Karl Mann1, Josef Frank2, Katrin Charlet3, Anne Beck3, Andreas Heinz3, Henrik Walter4, Marcella Rietschel2, Falk Kiefer1, Sabine Vollstädt-Klein1.   

Abstract

The aim of the current study was to determine genotype effects of four single nucleotide polymorphisms (SNPs) in the genes of the N-Methyl-d-aspartate receptor (GRIN1, GRIN2A, GRIN2C) and kainate receptor (GRIK1), which have been previously associated with alcoholism, on behavior, neural cue-reactivity and drinking outcome. Eighty-six abstinent alcohol dependent patients were recruited from an in-patient setting. Neuropsychological tests, genotyping and functional magnetic resonance imaging (fMRI) were used to study genotype effects. GRIN2C risk allele carriers displayed increased alcohol cue-induced activation in the anterior cingulate cortex (ACC) and dorsolateral prefrontal cortex (dlPFC). Neural activation in the ACC positively correlated with craving for alcohol (r = 0.201, P = 0.032), whereas activation in the dlPFC showed a negative association (r = -0.215, P = 0.023). In addition, dlPFC activation predicted time to first relapse (HR = 2.701, 95%CI 1.244-5.864, P = 0.012). GRIK1 risk allele carriers showed increased cue-induced activation in the medial prefrontal (PFC) and orbitofrontal cortex (OFC) and in the lateral PFC and OFC. Activation in both clusters positively correlated with alcohol craving (rmedOFC, medPFC  = 0.403, P = 0.001, rlatOFC, latPFC  = 0.282, P = 0.008), and activation in the cluster that encompassed the medial OFC predicted time to first relapse (HR = 1.911, 95%CI 1.030-3.545, P = 0.040). Findings indicate that SNPs in the GRIN2C and GRIK1 genes are associated with altered cue-induced brain activation that is related to craving for alcohol and relapse risk.
© 2015 Society for the Study of Addiction.

Entities:  

Keywords:  Alcoholism; cue-reactivity; fMRI; glutamate receptors; relapse; single nucleotide polymorphisms

Mesh:

Substances:

Year:  2015        PMID: 26289945     DOI: 10.1111/adb.12291

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  13 in total

1.  NMDA receptor GluN2A subunit deletion protects against dependence-like ethanol drinking.

Authors:  Nicholas J Jury; Anna K Radke; Dipanwita Pati; Adrina Kocharian; Masayoshi Mishina; Thomas L Kash; Andrew Holmes
Journal:  Behav Brain Res       Date:  2018-06-25       Impact factor: 3.332

Review 2.  Comorbid HIV infection and alcohol use disorders: Converging glutamatergic and dopaminergic mechanisms underlying neurocognitive dysfunction.

Authors:  Laura L Giacometti; Jacqueline M Barker
Journal:  Brain Res       Date:  2019-08-14       Impact factor: 3.252

3.  COMT and BDNF Gene Variants Help to Predict Alcohol Consumption in Alcohol-dependent Patients.

Authors:  Anna Klimkiewicz; Anna Mach; Andrzej Jakubczyk; Jakub Klimkiewicz; Anna Wnorowska; Maciej Kopera; Sylwia Fudalej; Margit Burmeister; Kirk Brower; Marcin Wojnar
Journal:  J Addict Med       Date:  2017 Mar/Apr       Impact factor: 3.702

Review 4.  Role of glutamatergic system and mesocorticolimbic circuits in alcohol dependence.

Authors:  Fawaz Alasmari; Sunil Goodwani; Robert E McCullumsmith; Youssef Sari
Journal:  Prog Neurobiol       Date:  2018-10-11       Impact factor: 11.685

Review 5.  Do specific NMDA receptor subunits act as gateways for addictive behaviors?

Authors:  F W Hopf
Journal:  Genes Brain Behav       Date:  2016-11-18       Impact factor: 3.449

Review 6.  Toward biomarkers of the addicted human brain: Using neuroimaging to predict relapse and sustained abstinence in substance use disorder.

Authors:  Scott J Moeller; Martin P Paulus
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-03-18       Impact factor: 5.067

7.  A novel NMDA receptor-based intervention to suppress compulsion-like alcohol drinking.

Authors:  Scott Andrew Wegner; Bing Hu; Thatiane De Oliveira Sergio; David Darevsky; Claudina Choi-Yan Kwok; Kelly Lei; Frederic Woodward Hopf
Journal:  Neuropharmacology       Date:  2019-06-25       Impact factor: 5.250

8.  A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus.

Authors:  Mehran Zare-Bidoky; Arshiya Sangchooli; Hamed Ekhtiari; Amy C Janes; Marc J Kaufman; Jason A Oliver; James J Prisciandaro; Torsten Wüstenberg; Raymond F Anton; Patrick Bach; Alex Baldacchino; Anne Beck; James M Bjork; Judson Brewer; Anna Rose Childress; Eric D Claus; Kelly E Courtney; Mohsen Ebrahimi; Francesca M Filbey; Dara G Ghahremani; Peyman Ghobadi Azbari; Rita Z Goldstein; Anna E Goudriaan; Erica N Grodin; J Paul Hamilton; Colleen A Hanlon; Peyman Hassani-Abharian; Andreas Heinz; Jane E Joseph; Falk Kiefer; Arash Khojasteh Zonoozi; Hedy Kober; Rayus Kuplicki; Qiang Li; Edythe D London; Joseph McClernon; Hamid R Noori; Max M Owens; Martin P Paulus; Irene Perini; Marc Potenza; Stéphane Potvin; Lara Ray; Joseph P Schacht; Dongju Seo; Rajita Sinha; Michael N Smolka; Rainer Spanagel; Vaughn R Steele; Elliot A Stein; Sabine Steins-Loeber; Susan F Tapert; Antonio Verdejo-Garcia; Sabine Vollstädt-Klein; Reagan R Wetherill; Stephen J Wilson; Katie Witkiewitz; Kai Yuan; Xiaochu Zhang; Anna Zilverstand
Journal:  Nat Protoc       Date:  2022-02-04       Impact factor: 17.021

9.  Antagonism of GluK1-containing kainate receptors reduces ethanol consumption by modulating ethanol reward and withdrawal.

Authors:  Natalia A Quijano Cardé; Erika E Perez; Richard Feinn; Henry R Kranzler; Mariella De Biasi
Journal:  Neuropharmacology       Date:  2021-09-10       Impact factor: 5.250

10.  FMRI-based prediction of naltrexone response in alcohol use disorder: a replication study.

Authors:  Patrick Bach; Georg Weil; Enrico Pompili; Sabine Hoffmann; Derik Hermann; Sabine Vollstädt-Klein; Falk Kiefer; Karl Mann; Wolfgang H Sommer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-04-21       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.